You cut your finger? Patch it up with a band aid and let the healing begin. How convenient would it be if this would work in an eye. If you can cure blinding eye diseases with a band aid, or at least slow them down.Those band aids are in the making; researchers from the department of Human Genetics developed six new molecular patches for treatment of the hereditary Stargardt disease. This month, Rob Collin and Frans Cremers published about it in the leading journal Genetics in Medicine.
Stargardt disease is an eye disorder that leads to visions loss, starting with a blurred spot in the centre of both eyes. “If you have Stargardt disease, the dropout starts there”, explains Cremers.
The disease usually manifests itself at a young age, in adolescents and young adults, and worsens greatly over time. Patients usually do not completely go blind, but it comes close: watching TV or driving a car becomes very difficult within a timespan of twenty years. Cremers: "It’s often emotionally extra tough that the diagnosis comes at a young age, when people are just starting to choose an education or start a career. They often have to completely change their plans.”
DNAStargardt disease is hereditary and occurs in roughly 1 in 10,000 people. That is almost 800,000 patients worldwide. They were unlucky to be born with two ABCA4 defects in their DNA that lead to the eye condition. The two errors - genetic mutations - are inherited from the parents, one from the mother and one from the father.
Treatment does not exist yet, but comes closer thanks to the molecular band aids of Rob Collin. "With such a band aid we can ‘block’ the mistakes," he says. "Errors in the DNA cause a disturbed function of the proteins in our eyes. The protein in question, ABCA4, normally cleans up waste products.” This doesn’t work properly due to these errors in the DNA. In time, the cells that provide sharp vision and let us discriminate colors, the so-called cones, gradually break down. “By masking the mutations, the cells will eventually start producing good proteins again.”
Band AidA similar kind of molecular band aid was developed a few years ago for a type of inborn blindness. For this retinal disorder, Cremers and his colleagues also succeeded to detect errors in patient’s DNA. Through a collaboration with the company ProQR Therapeutics from Leiden, the technique was put into practice. With good results: in several patients an improvement of the vision was measured following administration of the molecular band-aid.
Such a molecular band aid is quite different than the household band aids we all know from our medicine cabinets. The miniature plaster is in fact a synthetic RNA molecule (RNA is the intermediate state in the conversion of DNA into proteins), dissolved in a liquid and is injected into the eye by an ophthalmologist. The band aid finds its way to the correct cell and blocks exactly that part of the RNA that causes the wrong proteins. After this, the body will produce only healthy proteins. Whilst in the case of hereditary blindness an improvement in vision was measured, the band aid in Stargardt disease is primarily intended to ensure that vision does not deteriorate any further. The sooner the treatment starts, the more vision can be retained.
Stem cellsTo make sure the band aid covers the right parts, it must be clear where exactly the mutations are. Recent research of the group of Cremers has led to the creation of a large number of extra spots in our DNA where the mutations can be found. These findings are remarkable because the errors cannot be found in the usual regions of DNA. Instead they were located in regions between the places where diagnostics normally takes place. Cremers: “The ABCA4 gene consists of approximately 130,000 building blocks, of which 6,819 are examined during a regular genetic test. In this study, colleagues Riccardo Sangermano, Alex Garanto and Mubeen Khan have looked at all 130,000 building blocks.” In this week’s publication (Sangermano et al. 2019), the researchers describe how they investigated 36 patients with Stargardt disease, with only 1 previously identified mutation. Thanks to the new method, the second mutation was found in 24 of them, crucial knowledge to make a suitable molecular band aid. Cremers: “Since this publication, we have found a few more already.”
In some cases, detecting abnormalities in the RNA is only possible by looking at the eye cells of a patient. Because these can’t easily be extracted from a living eye, the researchers previously developed a method to grow retinal cells based on skin cells from patients, via so-called stem cell technology (Albert et al. 2018).
MillionsThe improvements are the result of an accumulation of scientific studies in recent years. Five grants from patient organizations and scientific institutions from the Netherlands, the EU and the USA provided the necessary millions needed in the fight against eye diseases, including a respectable EU subsidy for a Marie Curie Training Network called StarT. Thanks to the several studies, a large group of mutations has now been identified that cause Stargardt disease. Every combination of mutations requires a different band aid. If Stargardt disease is diagnosed, future healthcare providers therefore must determine the errors involved. Collin: “If Stargardt disease is diagnosed, doctors can now use the patient's blood to analyse all causal mutations in the ABCA4 gene. This way you can find out which errors are causing it and, subsequently, which band aid may work.”
Sangermano et al. 2019
Albert et al. 2018
Related news items
Social media posts on medication use during pregnancy often incorrect23 August 2019
Dutch social media regularly post about the safety of medicines for pregnant women. Many pregnant women use these posts as a source of information. A new analysis shows, however, that information found on social media about the risk of medication use often does not correspond with guidelines.read more
Hans van Bokhoven newly elected in Academia Europaea22 August 2019
The Academia Europaea is a functioning European Academy of Humanities, Letters and Sciences, composed of individual members.read more
Drug-induced interstitial lung disease in advanced breast cancer patients receiving everolimus22 August 2019
In Targeted Oncology, Annelieke Willemsen, Carla van Herpen and colleagues, showed that pulmonary function test with diffusion capacity of the lungs for carbon monoxide and serum biomarkers can be of aid to differentiate everolimus-related interstitial lung disease from other respiratory problems.read more
Publication in PNAS on dissecting EEC syndrome using single-cell RNA-seq22 August 2019
PhD candidates Eduardo Soares and Quan Xu in Jo Huiqing Zhou’s group in Molecular Developmental Biology, theme Reconstruction and regenerative medicine, have published a paper in PNAS on the disease mechanism of EEC syndrome using single-cell RNA-seq technology and patient-derived iPSCs.read more
Patient trust and participation in cell biological research21 August 2019
Alessandra Cambi and Gert Olthuis, discuss key ethical issues inherent in the development and the value of building trust and trustworthiness.read more
NWO grant for a tissue-generating patch to close diaphragmatic defects21 August 2019
Willeke Daamen and Toin van Kuppevelt, theme Reconstructive and regenerative medicine, were recently awarded a 690 k€ grant by NWO, domain Applied & Engineering Sciences, for the development of advanced patches for closure of diaphragmatic defects in children with congenital diaphragmatic hernia.read more